| Autor: |
Loibl S; Sibylle Loibl, MD, PhD, German Breast Group c/o GBG Forschungs GmbH, Neu-Isenburg, Germany, Center for Hematology and Oncology Bethanien, Frankfurt, Germany; Valentina Nekljudova, PhD, German Breast Group c/o GBG Forschungs GmbH, Neu-Isenburg, Germany; and Carsten Denkert, MD, PhD, Institute of Pathology, University Hospital Marburg and Philipps-University Marburg, Marburg, Germany., Nekljudova V; Sibylle Loibl, MD, PhD, German Breast Group c/o GBG Forschungs GmbH, Neu-Isenburg, Germany, Center for Hematology and Oncology Bethanien, Frankfurt, Germany; Valentina Nekljudova, PhD, German Breast Group c/o GBG Forschungs GmbH, Neu-Isenburg, Germany; and Carsten Denkert, MD, PhD, Institute of Pathology, University Hospital Marburg and Philipps-University Marburg, Marburg, Germany., Denkert C; Sibylle Loibl, MD, PhD, German Breast Group c/o GBG Forschungs GmbH, Neu-Isenburg, Germany, Center for Hematology and Oncology Bethanien, Frankfurt, Germany; Valentina Nekljudova, PhD, German Breast Group c/o GBG Forschungs GmbH, Neu-Isenburg, Germany; and Carsten Denkert, MD, PhD, Institute of Pathology, University Hospital Marburg and Philipps-University Marburg, Marburg, Germany. |
| Abstrakt: |
Competing Interests: Sibylle LoiblHonoraria: Chugai PharmaConsulting or Advisory Role: Pfizer, Roche, Novartis, Seattle Genetics, Celgene, Lilly, AstraZeneca/MedImmune, Bristol Myers Squibb, Merck KGaA, AbbVie, Amgen, Medscape, Daiichi Sankyo, Samsung, Puma Biotechnology, Pierre Fabre, Immunomedics, GlaxoSmithKline, EirGenix, BayerResearch Funding: AbbVie, AstraZeneca, Amgen, Celgene, Novartis, Pfizer, Roche, Immunomedics, Daiichi SankyoPatents, Royalties, Other Intellectual Property: Patent Pending EP14153692.0 Carsten DenkertStock and Other Ownership Interests: Sividon DiagnosticsHonoraria: Novartis, RocheConsulting or Advisory Role: MSD Oncology, Daiichi Sankyo, Molecular Health, AstraZeneca, MerckResearch Funding: Myriad Genetics, RochePatents, Royalties, Other Intellectual Property: VMScope digital pathology software, Patent applications WO2015114146A1 and WO2010076322A1—therapy response, Patent application WO2020109570A1—cancer immunotherapyTravel, Accommodations, Expenses: RocheNo other potential conflicts of interest were reported. |
